Early screening of lung cancers:an effort arduous but worthwhile

Cancers are a concerning health catastrophe worldwide that may become the end of lifetime for many of us--they overwhelmingly exhaust medical resources, lead to huge economic burdens, and separate people from their beloved ones. Fewer and fewer insurance agencies are willing to include primary cancers on their general health insurance plan, just because cancers have been so flummoxingly usual in our daily life that many primary cancer claims would give rise to much less profits.

Simultaneous Bilateral Thoracoscopic Pneumonectomy for Early Multiple Primary Lung Cancer Feasibility Analysis

Objective:To analyze the feasibility of simultaneous bilateral thoracoscopic lung resection in the treatment of multiple primary lung cancers in the early stage.Methods:The study time range is between March 2019 and March 2021.A sample of 30 patients with early multiple primary lung cancer admitted to this hospital were included,and they were divided into a study group,a control group,and samples within the group using a random number table scheme n=15,patients in the control group underwent staged bilateral thoracoscopic pneumonectomy,and patients in the study group underwent bilateral thoracoscopic pneumonectomy at the same time.The indicators of the two groups were compared and analyzed.Results:There was no significant difference in the operation time and intraoperative blood loss between the two groups(P>0.05).There were significant differences in the VAS score,total length of hospital stay,and total surgical costs on the first day after surgery(P<0.05);there was no significant difference in the two groups'postoperative recovery indicators and the incidence of complications(P>0.05).Conclusion:It is safe and feasible to treat patients with multiple primary lung cancer in both lungs at the same time with simultaneous bilateral thoracoscopic surgery,and is suitable for promotion.

Determination of breath isoprene in 109 suspected lung cancer patients using cavity ringdown spectroscopy

Background:Lung cancer is one of the most common malignant tumors worldwide.Currently,effective screening methods for early lung cancer are still scarce.Breath analysis provides a promising method for the pre-screening or early screening of lung cancer.Isoprene is a potential and important breath biomarker of lung cancer.Material and Methods:To investigate the clinical value of isoprene for diagnosing lung cancer patients,a cavity ringdown spectroscopy(CRDS)based near-real time,sensitive analysis method of breath isoprene is developed in our lab.In this paper,92 breath samples from lung cancer patients,17 breath samples from patients with benign lesions,and 107 breath samples from healthy people were collected.Results:Research indicates that breath isoprene concentration is significantly higher in healthy individuals(221:3±122:2 ppbv)than in patients with lung cancer(112:0±36:6 ppbv)and benign lung lesions(127:9±41:2 ppbv).The result of Receiver Operating Characteristic(ROC)curve suggests that the concentration of isoprene is meaningful for the diagnosis of lung cancer(AUC=0:822,sensitivity=63:6%,specificity=90:2%,P<0:01).Conclusion:This study demonstrates that the CRDS breath isoprene analysis system can effectively analyze a large sample of human breath isoprene,and preliminarily confirms the use of breath isoprene as a biomarker for lung diseases.

Early Diagnostic Value of Circulating MiRNA-21 in Lung Cancer: A Meta-Analysis

To evaluate the early diagnostic value of circulating miRNA-21 in diagnosis of lung cancer, databases such as Wan Fang, VIP, PubMed, and Elsevier were systematically searched from 2005 to 2013 to collect relevant references in which the diagnostic value had been evaluated. The statistics were consolidated and the qualities of the studies were classified. The data were analyzed using Meta Disc1.4 software. The diagnostic value of circulating miRNA-21 in lung cancer was assessed by pooling sensitivity, specificity, the likelihood ratio, and the Summary Receiver Operating Characteristic（SROC） curve. Publication biases of the studies involved were analyzed using Stata 11.0 software. A total of 143 papers were collected of which 8 were included, which contained 600 cases and440 controls. A heterogeneity test proved the existence of homogeneity in this study. Upon analysis using random effects models, the weighted sensitivity was 0.68, the specificity 0.77, the positive likelihood ratio 2.84, the negative likelihood ratio 0.40, and the SROC Area Under the Curve（AUC） was 0.8133. Further analysis by subgroup showed that the 5 indicators mentioned above were 0.72, 0.84, 4.50, 0.27, and 0.8987, respectively, for the serum group and 0.63, 0.70, 1.95, 0.53, and 0.7318, respectively, for the plasma group. We conclude that circulating miRNA-21can be regarded a valuable reference in diagnosis of lung cancer. This research showed that in lung cancer the early diagnostic value of miRNA-21 in serum was better than that in plasma.

Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing lung cancer patients from healthy people

Screening and early diagnosis of lung cancer relies mainly on chest X-ray, low-dose computed tomography, bronchoscopy, sputum cytology, and measurement of tumor markers such as carcinoembryonic antigen (CEA), cytokeratin-19 fragments (Cyfra21-1), and neuron-specific enolase (NSE). However, all these methods lack adequate sensitivity and/or specificity. 1-3 Better methods are therefore urgently needed in screening and early diagnosis of lung cancer, and proteomic fingerprinting represents a promising approach. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), an innovative proteomic technology, has overcome many of the limitations of two-dimensional electrophoresis (2D) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). 4,5 Recently, this technology has been successfully used to distinguish pancreatic, ovarian and prostate cancer patients from healthy control subjects. 5-7 The aim of the current study was to investigate the application of serum SELDI protein profiling in distinguishing lung cancer patients from healthy persons.

Prognosis and staging of superficial endobronchial lung cancer： the impact of invasion depth, tumor diameter, and coexistent pneumonitis or atelectasis

Background There are few reports discussing the surgical pathological characteristics of superficial endobronchial lung cancer （SELC） defined as cancer growth limited to the bronchial wall. Its prognosis and corresponding TNM staging have not been fully clarified. Little is known as to whether T status is impacted by the existence of associated atelectasis or pneumonia （which might be controversial, indicating either T1 or T2）, and circumstantial invasion depth.Methods Between 1988 and 2007, 81 out of 8817 surgically treated patients met SELC criteria; there was no detectable invasion beyond the bronchial wall. A retrospective review was performed and follow-up information was collected.Results The overall five-year survival rate of 81 patients was 85.6%; for NOM0 （n=67）, N1M0 （n=7） and N2M0 （n=7）patients, they were 89.3%, 75.0% and 60.0%, respectively. Intraluminal tumor size measured from 0.4 to 3.0 cm;obstructive atelectasis or pneumonia was noted in 14 patients. The presence of tumor-associated obstructive atelectasis or pneumonia did not have a significant impact upon prognosis （P=0.96）, nor did the greatest diameter of the tumor （P=0.70）. Histology showed carcinoma in situ （level one） in 13 cases; invasion of the submucosal layer （level two） in 12,involvement of the muscular layer （level three） in 20, invasion into the space between the muscular layer and cartilage （level four） in 21, and bronchial cartilage infiltration in 15 （level five）. In cases without lymphnode metastases, five-year survival was 100% for the first three levels and 84.0% and 61.3% for the level four and level five.Conclusions Relative to TNM-based prognostic data, superficial endobronchial lung cancer exhibits increased five-year survival rates, and therefore should be placed at the forefront among tumors in the T1 class, regardless of tumor size or the presence of secondary obstructive atelectasis or pneumonia. Lymphnode metastasis is associated with a worse prognosis. Survival is negatively impacted by tumor infiltration depth into the bronchial wall.